SynthesisMolecular neurobiology2026
The Role of MicroRNA in Diagnosis of Huntington's Disease: A Systematic Review.
Synthesis in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntington's disease (HD) is an autosomal dominant genetic neurodegenerative disorder with features of progressive motor, cognitive, and psychiatric dysfunction. Current diagnosis relies largely on clinical presentation and genetic testing but lacks sensitivity to early disease diagnosis or progression monitoring. MicroRNAs (miRNAs) are short non-coding RNA molecules that regulate gene expression post-transcriptionally. They are increasingly being investigated as potential diagnostic biomarkers, especially given their detectability in biofluids like plasma and cerebrospinal fluid. This review aimed to evaluate the clinical utility of miRNAs in HD, specifically defining their roles not as primary diagnostic screeners, but as dynamic biomarkers for predicting clinical conversion in premanifest individuals, tracking disease progression, and monitoring therapeutic responses. A comprehensive literature search was conducted in Medline, Embase, PubMed, Scopus, Cochrane, and ClinicalTrials.gov up to November 2024. Studies written in English including human subjects or HD models quantifying miRNA expression level for diagnostic purposes were included in this systematic review. Data was extracted onto a standard form and quality assessed with the MINORS and Cochrane tools. Thirty studies with 1889 participants were included. Dysregulated miRNAs that had been repeatedly identified in HD were miRNA-9, miRNA-124, miRNA-214, miRNA-146a, and miRNA-10b. Remarkably, Romano et al. have attained 88% sensitivity and 92% specificity for SNORD13 in plasma, and Chang et al. have achieved AUC > 0.90 for a multi-miRNA panel. While promising trends, high heterogeneity of methods and incomplete reporting of diagnostic metrics limited meta-analysis. miRNAs, particularly exosome-derived ones, possess great potential as minimally invasive biomarkers for HD diagnosis. However, while current evidence strongly supports this biomarker potential, immediate clinical implementation is not yet feasible. Future studies must resolve ongoing challenges in assay standardization, cross-cohort external validation, and integration with clinical and imaging data before clinical deployment can be realized.
Indexed as
Identifiers
42631818What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.